{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:29:29Z","timestamp":1771014569805,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Eisai Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.clml.2013.02.020","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T21:11:14Z","timestamp":1371157874000},"page":"377-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Duration of Response in Cutaneous T-Cell Lymphoma Patients Treated With Denileukin Diftitox: Results From 3 Phase III Studies"],"prefix":"10.1016","volume":"13","author":[{"given":"Madeleine","family":"Duvic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa","family":"Geskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.02.020_bib1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1309\/AJCP09OTJOYAVZZK","article-title":"Simplified flow cytometric assessment\u00a0in mycosis fungoides and Sezary syndrome","volume":"136","author":"Hristov","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2013.02.020_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.02.020_bib3","first-page":"1985","article-title":"Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome)","volume":"85","author":"Jones","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.02.020_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.135.1.26","article-title":"Clinical characteristics and long-term outcome of patients with generalized patch and\/or plaque (T2) mycosis fungoides","volume":"135","author":"Kim","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2013.02.020_bib5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients\u00a0with mycosis fungoides and Sezary syndrome","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2013.02.020_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2013.02.020_bib7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/archderm.1993.01680270085011","article-title":"Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA","volume":"129","author":"Mostow","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2013.02.020_bib8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2005.00497.x","article-title":"Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides","volume":"75","author":"Rupoli","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2013.02.020_bib9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.02.020_bib10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2013.02.020_bib11","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.02.020_bib12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1084\/jem.167.2.612","article-title":"Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein","volume":"167","author":"Bacha","year":"1988","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2013.02.020_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/eji.1830200412","article-title":"Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells","volume":"20","author":"Waters","year":"1990","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clml.2013.02.020_bib14","doi-asserted-by":"crossref","first-page":"11885","DOI":"10.1016\/S0021-9258(19)38482-0","article-title":"Structure\/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells","volume":"265","author":"Williams","year":"1990","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2013.02.020_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.02.020_bib16","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15S","key":"10.1016\/j.clml.2013.02.020_bib17","article-title":"Efficacy and safety of denileukin difitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: integrated analysis of three large phase III trials","volume":"26","author":"Negro-Vilar","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.02.020_bib18","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jaad.2011.12.027","article-title":"Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides\/Sezary syndrome receiving placebo","volume":"67","author":"Prince","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2013.02.020_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/10428194.2012.706286","article-title":"Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sezary syndrome","volume":"54","author":"Prince","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.02.020_bib20","series-title":"Ontak [package insert]","year":"2011"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013000955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013000955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:34Z","timestamp":1761870214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013000955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S2152265013000955"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.02.020","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of Response in Cutaneous T-Cell Lymphoma Patients Treated With Denileukin Diftitox: Results From 3 Phase III Studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}